Diagnostic methods are evolving to measure the reaction of the host to a specific disease challenge rather than attempting to directly detect an antibody or pathogen.
CNAD’s technology platform delivers a repeatable and scalable process for molecular diagnostic assay development. Our bioinformatics platform and
We develop diagnostic assays that can be run in a matter of hours on standard equipment. CNAD has successfully demonstrated proof of concept with studies completed on radiation in rats, chronic wasting in elk, bovine spongiform encephalopathy (BSE) in cattle, and sepsis in humans.
CNAD’s proprietary technology provides the possibility for accurate diagnostic tests to be used in the early stages of chronic diseases. CNAD’s technology uses
© 2019 CNA Diagnostics Inc.